MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of shares...
    • Impairment loss on other intangi...
    • Loss on debt extinguishment
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Gain on settlement of current li...
    • Deferred income tax benefit
    • Others

Cash Flow
2025-12-31
Net loss
-17,298
Stock-based compensation
2,890
Issuance of shares for services
27
Accretion of debt issuance costs
589
Gain on settlement of current liabilities
2,984
Loss on debt extinguishment
-3,164
Change in fair value of warrant liabilities
775
Impairment loss on other intangible assets
5,180
Loss on derivative liability
-230
Deferred income tax benefit
-1,088
Unrealized foreign currency exchange losses (gains)
99
Prepaid expenses and other current assets
-594
Accounts payable and accrued expenses
-998
Net cash used in operating activities
-10,568
Proceeds from issuance of shares, net of issuance costs
10,725
Proceeds from issuance of warrants
1,036
Proceeds from issuance of notes payable
2,099
Repayment of notes payable and convertible notes
553
Proceeds from employee vesting of restricted shares
33
Proceeds from pre-funded warrants
330
Payments on seller-financed purchases
499
Net cash provided by financing activities
13,171
Effect of exchange rates on cash
1
Net change in cash
2,604
Cash and restricted cash at beginning of period
2,659
Cash and restricted cash at end of period
5,263
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofshares, net of issuance...$10,725K Proceeds from issuance ofnotes payable$2,099K Proceeds from issuance ofwarrants$1,036K Proceeds from pre-fundedwarrants$330K Proceeds from employeevesting of restricted...$33K Net cash provided byfinancing activities$13,171K Effect of exchangerates on cash$1K Canceled cashflow$1,052K Net change in cash$2,604K Canceled cashflow$10,568K Repayment of notes payableand convertible...$553K Payments onseller-financed purchases$499K Impairment loss on otherintangible assets$5,180K Loss on debtextinguishment-$3,164K Stock-based compensation$2,890K Prepaid expenses andother current assets-$594K Accretion of debt issuancecosts$589K Loss on derivativeliability-$230K Issuance of shares forservices$27K Net cash used inoperating activities-$10,568K Canceled cashflow$12,674K Net loss-$17,298K Gain on settlement ofcurrent liabilities$2,984K Deferred income taxbenefit-$1,088K Accounts payable andaccrued expenses-$998K Change in fair value ofwarrant liabilities$775K Unrealized foreigncurrency exchange losses...$99K

Akari Therapeutics Plc (AKTX)

Akari Therapeutics Plc (AKTX)